Nucleome Therapeutics

Nucleome Therapeutics is a cutting-edge biotech startup that focuses on unlocking the non-coding genome to improve human health. The company leverages advanced understanding of genetic variations to identify pathways affected by diseases and discover new drug targets, particularly for autoimmune diseases—a market valued at over $35 billion.

Nucleome Therapeutics operates in the biotechnology and pharmaceutical sectors, serving clients such as pharmaceutical companies, research institutions, and healthcare providers. The company’s proprietary platform combines expertise in bioinformatics (the use of software and computational methods to understand biological data), genomics (the study of genomes), and the 3D structure of chromosomes. This platform is built on research from the University of Oxford and utilizes machine learning and 3D chromosomal analysis to link genetic variants to the gene targets they influence. This approach helps in identifying high-quality, low-risk drug targets across various diseases.

The business model of Nucleome Therapeutics revolves around the discovery and validation of new drug targets. The company makes money by partnering with pharmaceutical companies for drug development, licensing its technology, and potentially through drug repurposing (finding new uses for existing drugs). The company’s unique combination of computational and experimental methods allows it to validate targets at scale, making it a valuable partner in the drug discovery process.

Founded in 2019 as a spin-out from the University of Oxford, Nucleome Therapeutics has built its foundation on a decade of research and initial seed investment. The company aims to expand its applications to other cell types and explore new partnerships for further growth.

Keywords: biotech, genomics, autoimmune diseases, drug discovery, bioinformatics, 3D chromosomes, machine learning, University of Oxford, pharmaceutical partnerships, non-coding genome.